Heidi Berdin, MD
Pulmonary Disease · Lake Havasu City, AZNPI 1659368751
Payments from drug & device makers
Across 587 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$2K
- Merck$920
- Intuitive Surgical$847
- Actelion Pharmaceuticals US, Inc.$835
- Mylan Specialty L.p.$831
- plus $5K from 26 others
What the payments were for
- Travel & lodging$6775%
- Food & beverage$12,92295%
- Education$630%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 156 | $3,712 |
| GSK | 88 | $1,905 |
| Merck | 24 | $920 |
| Intuitive Surgical | 6 | $847 |
| Actelion Pharmaceuticals US, Inc. | 22 | $835 |
| Mylan Specialty L.p. | 83 | $831 |
| United Therapeutics Corporation | 23 | $600 |
| Electromed, Inc. | 47 | $564 |
| Boehringer Ingelheim | 27 | $555 |
| Regeneron Healthcare Solutions, Inc. | 10 | $286 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $258 |
| Biohaven Pharmaceuticals, Inc. | 2 | $250 |
| Insmed, Inc. | 12 | $248 |
| Philips North America LLC | 12 | $220 |
| Inspire Medical Systems, Inc. | 2 | $208 |
| Baxter Healthcare | 8 | $183 |
| Verona Pharma, Inc. | 10 | $166 |
| Pulmonx Corporation | 3 | $149 |
| Sunovion Pharmaceuticals Inc. | 9 | $146 |
| Siemens Medical Solutions USA, Inc. | 1 | $138 |
| Genentech USA, Inc. | 5 | $100 |
| Grifols USA, LLC | 4 | $84 |
| Sanofi | 4 | $78 |
| Advanced Respiratory, Inc | 4 | $65 |
| Viatris Specialty LLC | 3 | $59 |
| Lilly USA, LLC | 2 | $51 |
| Gilead | 3 | $48 |
| Shire North American Group Inc | 2 | $43 |
| Itamar Medical Inc | 1 | $42 |
| 3b Medical, Inc. | 1 | $24 |
| Boston Scientific | 2 | $24 |
| Bayer | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$630
- BREZTRI$332
- NURTEC ODT$250
- ZERBAXA$244
- UPTRAVI$238
- WINREVAIR$123
- Inspire$121
- OPSUMIT$114
- TRELEGY ELLIPTA$111
- Pulmonx Endobronchial Valve EBV$107
- TEZSPIRE$104
- FASENRA$104
How this compares
$13,662 in reported general payments places this provider in the 75th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 663 | $633,951 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 665 | $629,781 |
| UptraviSelexipag | 13 | $281,389 |
| AdempasRiociguat | 17 | $212,696 |
| ZemairaAlpha-1-Proteinase Inhibitor | 13 | $169,426 |
| OpsumitMacitentan | 12 | $148,781 |
| OfevNintedanib Esylate | 12 | $95,985 |
| Spiriva RespimatTiotropium Bromide | 116 | $85,289 |
| NucalaMepolizumab | 18 | $69,234 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 77 | $67,493 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 93 | $53,263 |
| SymbicortBudesonide/Formoterol Fumarate | 117 | $41,527 |
| Spiriva HandihalerTiotropium Bromide | 40 | $37,467 |
| Breo ElliptaFluticasone/Vilanterol | 84 | $34,532 |
| EliquisApixaban | 41 | $29,921 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,905 | $811,639931 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Airsupra | $3,712 | $685,674813 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $835 | $430,16925 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $555 | $265,583225 claims |
| BayerAdempas | $23 | $212,69617 claims |
| MerckDulera | $920 | $7,83321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Lake Havasu City
- Muhammad SalimChandler$5.9M
- Vikas SayalBullhead City$3.7M
- David BaratzPhoenix$2.2M
- James RossPhoenix$2M
- Rajat WaliaPhoenix$1.9M
- Robert OrrPeoria$1.6M
- Sachin ChaudharyTucson$1.2M
- Mark GotfriedPhoenix$1.1M
- George ParidesMesa$913K
- Richard SueGilbert$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.